迈瑞医疗(300760) - 2024 Q2 - 季度财报

Financial Performance - The company's total revenue for the first half of 2024 reached 205.3 billion CNY, with a year-on-year growth of 18.1%[8] - Net profit attributable to shareholders was 75.6 billion CNY, reflecting a year-on-year increase of 11.1%[2] - Operating cash flow for the period was 85.0 billion CNY, with a year-on-year growth of 24.0% in Q2[2] Segment Performance - The in-vitro diagnostics segment generated revenue of 76.6 billion CNY, marking a year-on-year growth of 28.2% and accounting for 37.3% of total revenue[3] - The medical imaging business reported revenue of 42.7 billion CNY, with a year-on-year increase of 15.5%[3] - Revenue from the life information and support segment was 80.1 billion CNY, a decrease of 7.6% year-on-year[4] Research and Development - R&D investment totaled 19.4 billion CNY, representing 9.4% of total revenue[4] International Markets - The company achieved significant growth in international markets, with European revenue reaching 15.0 billion CNY, up 37.9% year-on-year[4] Project Developments - The "瑞影云++" project has installed over 13,000 units across 31 provinces, with nearly 2,400 new installations in the first half of 2024[5] - The company has successfully treated 280 patients in public places with its AED devices as of June 30, 2024[5]